The team will use the five-year funding to develop a liquid biopsy-based assay to select and prioritize liver cancer patients who need a liver transplant.
Agilent, which co-led Mission Bio's 2018 $30 million Series B financing round, will comarket the Tapestri platform to cancer researchers in North America.
A number of manufacturers say that the shortage of swabs and transport media for facilitating SARS-CoV-2 testing that clinicians are facing will soon abate.
The team has begun analyzing additional analytes in HER2-positive breast cancer patients and will present preliminary results at AACR's annual meeting in May.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
The Stanford University spinout claims it can get three times the nucleic acid yield as column- or magnetic bead-based methods, with less damage to the molecules.
Through a startup called FCS Technology, the team is hoping to market the platform for cancer research and, eventually, clinical diagnostic applications.
Under the terms of the non-exclusive agreement, the companies have made Diagenode's D-Plex library preparation products available on MGI's sequencing platforms.
Bioinformatics firm Next Gen Diagnostics will integrate Fluidigm's Juno microfluidic sample prep system into its workflow for pathogen whole-genome sequencing.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.
